SAN ANTONIO, June 7, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that smaller doses of epratuzumab labeled with yttrium-90 (90Y) given repeatedly to elderly patients with diffuse large B-cell lymphoma (DLBCL) appears to improve their response to the combination of rituximab and CHOP chemotherapy (R-CHOP), the standard of care for this disease.
